glucagon

Glucagon (1-29), bovine, human, porcine is a hormone produced by pancreatic α-cells with glucagon activity, which promotes glycogenolysis and gluconeogenesis, and is used in the study of obesity and diabetes.

Glucagon significantly impacts protein and amino acid metabolism. It hinders the integration of amino acids into the proteins of the liver, muscle, and pancreas, augmenting nitrogen excretion and stimulating hepatic urea synthesis. Additionally, it elevates hepatic transaminase and urea cycle enzyme levels. Glucagon also enhances hepatic amino acid uptake, facilitating their conversion into liver glycogen, and reduces blood amino acid concentrations [1].

LGD-6972 is an antagonist of glucagon receptor.

Saxagliptin hydrate (Onglyza hydrate) is a selective and reversible DPP4 inhibitor (IC50: 26 nM; Ki: 1.3 nM).

AZD-1656 is a glucokinase activator (GKA) that can cause dose-limiting hypoglycemia in normal animals used in embryofetal development studies and type 2 diabetes.

Saxagliptin (BMS-477118) is a selective, reversible DPP4 inhibitor with an IC50 of 26 nM.

PF-06291874 (Glucagon receptor antagonists-4) (Glucagon receptor antagonists-4) is a highly effective and orally active antagonist of the glucagon receptor.

Glucagon receptor antagonist -1 is a highly effective glucagon receptor antagonist.

Glucagon receptor antagonist -2 is a highly effective glucagon receptor antagonist.

Glucagon receptor antagonist -3 is a highly effective glucagon receptor antagonist.

Glucagon receptor antagonists-5 is an orally bioavailable indazole-based glucagon receptor antagonist (Ki: 32 nM). It has potential for the treatment of type 2 diabetes mellitus (T2DM).

Glucagon receptor antagonist-10 (Compound 11) is a glucagon receptor antagonist with a pIC50 value of 7.154. It is employed in the study of glucose homeostasis.

Glucagon receptor antagonist-11 (Compound 14) is a glucagon receptor antagonist with a pIC50 value of 6.677. This compound, along with Glucagon receptor antagonist-10, is applicable in glucose homeostasis research.

Glucagon receptor antagonist-9 (compound 13) is a potent inhibitor of the glucagon receptor, with a pIC50 of 7.000.

[Des-His1,Glu9]-Glucagon amide TFA is a potent peptide antagonist of the glucagon receptor with a pA2 value of 7.2, demonstrating potential utility in diabetes pathogenesis research[1].

Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human, is a human GLP-1 (7-36) amide biotinylated at the C-terminal.

[Des-His1,Glu9] Glucagon, a powerful antagonist of the glucagon receptor system, plays a crucial role in enhancing the glucose-stimulated insulin release from pancreatic islet cells. This compound is utilized in diabetes research [1].

Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide, a biotin-labeled variant of glucagon-like peptide-1-(7-36), is a gastrointestinal peptide known for its antidiabetogenic properties, including enhancing insulin secretion [1] [2].

Biotinyl-Glucagon (1-29), encompassing human, bovine, and porcine versions, is a biotinylated form of glucagon. This peptide hormone, synthesized by the pancreas's α-cells, elevates glucose and fatty acid levels in the bloodstream [1] [2].

(Met(O)27)-Glucagon (1-29) (human, rat, porcine) is a modified glucagon exhibiting the same maximum glucose-synthesizing activity in rat hepatocytes as its native form, but with reduced potency, highlighting the importance of methionine in glucagon's attachment to hepatic receptors [1].

Glucagon (22-29) acts as a partial agonist of Glucagon (19–29) and independently inhibits the calcium (Ca2+) pump in liver plasma membranes without activating adenylate cyclase [1] [2].

"(Asp28)-Glucagon (1-29) (human, rat, porcine)" is an analog of glucagon with an aspartic acid (Asp) substitution at position 28, notably enhancing its aqueous solubility at physiological pH levels while retaining glucagon's innate biological activity [1].

Glucagon, a peptide hormone derived from proglucagon in pancreatic α cells, regulates glucose metabolism. It stimulates glucose production in rat hepatocytes ex vivo and enhances glucose output from perfused rat livers through elevated gluconeogenesis and glycogenolysis, while reducing glycolysis, and raises plasma glucose levels in rats. Glucagon secretion decreases following food intake in healthy rats and humans, yet remains unchanged or increases in individuals with type 2 diabetes.

Anti-Glucagon Antibody is an antibody targeting Glucagon and can be used for metabolism research.